Characterization of cancer omics and drug perturbations in panels of lung cancer cells

Sci Rep. 2019 Dec 20;9(1):19529. doi: 10.1038/s41598-019-55692-9.

Abstract

To better understand the disruptions of transcriptional regulations and gene expression in lung cancers, we constructed a multi-omics catalogue of the responses of lung cancer cells to a series of chemical compounds. We generated and analyzed 3,240 RNA-seq and 3,393 ATAC-seq libraries obtained from 23 cell lines treated with 95 well-annotated compounds. To demonstrate the power of the created multi-omics resource, we attempted to identify drugs that could induce the designated changes alone or in combination. The basal multi-omics information was first integrated into co-expression modules. Among these modules, we identified a stress response module that may be a promising drug intervention target, as new combinations of compounds that could be used to regulate this module and the consequent phenotypic appearance of cancer cells have been identified. We believe that the multi-omics profiles generated in this study and the strategy used to stratify them will lead to more rational and efficient development of anticancer drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Survival / genetics
  • Cell Survival / physiology
  • GTP Phosphohydrolases / genetics
  • Genes, erbB-1 / genetics
  • Genomics / methods*
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / metabolism*
  • Membrane Proteins / genetics
  • Metabolome / genetics
  • Metabolome / physiology
  • Phylogeny
  • Proto-Oncogene Proteins p21(ras) / genetics
  • RNA, Small Interfering / genetics

Substances

  • KRAS protein, human
  • Membrane Proteins
  • RNA, Small Interfering
  • GTP Phosphohydrolases
  • NRAS protein, human
  • Proto-Oncogene Proteins p21(ras)